Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2022-06-17 | 2022-07-28 | 162907 |
| APO-LEVOFLOXACIN | 250MG | TABLET | Resolved | 2022-07-15 | 2023-01-20 | 164719 |
| APO-LEVOFLOXACIN | 500MG | TABLET | Resolved | 2022-07-15 | 2022-08-06 | 164728 |
| APO-LEVOFLOXACIN | 500MG | TABLET | Resolved | 2022-09-30 | 2023-01-20 | 170766 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2022-11-11 | 2023-01-20 | 174359 |
| APO-LEVOFLOXACIN | 500MG | TABLET | Resolved | 2023-02-16 | 2023-05-19 | 185007 |
| APO-LEVOFLOXACIN | 250MG | TABLET | Resolved | 2023-02-16 | 2023-05-06 | 185010 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2023-02-23 | 2023-05-06 | 185468 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2023-12-06 | 2024-03-08 | 212569 |
| APO-LEVOFLOXACIN | 250MG | TABLET | Resolved | 2024-02-09 | 2024-03-08 | 219156 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2024-07-12 | 2024-07-26 | 232829 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2024-08-22 | 2024-11-08 | 235695 |
| APO-LEVOFLOXACIN | 500MG | TABLET | Resolved | 2025-05-01 | 2025-08-22 | 256319 |
| APO-LEVOFLOXACIN | 750MG | TABLET | Resolved | 2025-06-12 | 2025-07-18 | 260153 |
| APO-LEVOFLOXACIN | 250MG | TABLET | Resolved | 2025-07-03 | 2025-07-18 | 261626 |
| APO-LEVOTHYROXINE | 200MCG | TABLET | Actual shortage | 2025-05-15 | 2025-07-31 | 257519 |
| APO-LEVOTHYROXINE | 200MCG | TABLET | Resolved | 2025-05-15 | 2025-07-18 | 257525 |
| APO-LEVOTHYROXINE | 150MCG | TABLET | Resolved | 2025-06-12 | 2025-10-10 | 260156 |
| APO-LEVOTHYROXINE | 175MCG | TABLET | Resolved | 2025-06-12 | 2025-08-22 | 260159 |
| APO-LEVOTHYROXINE | 100MCG | TABLET | Resolved | 2025-06-12 | 2025-10-10 | 260162 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
| APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
| APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
| APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
| APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
| APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
| APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
| APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
| APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
| APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
| APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
| APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
| APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |